Ryvu Therapeutics S.A. (RVU.WA)
PLN 32.85
(1.39%)
PLN 32.85
(1.39%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.11 Million PLN | 20.41% |
| 2022 | 1.75 Million PLN | -10.11% |
| 2021 | 1.95 Million PLN | 16.78% |
| 2020 | 1.67 Million PLN | 5.65% |
| 2019 | 1.58 Million PLN | -20.27% |
| 2018 | 1.98 Million PLN | 25.04% |
| 2017 | 1.59 Million PLN | 13.39% |
| 2016 | 1.4 Million PLN | 19.52% |
| 2015 | 1.17 Million PLN | 66.22% |
| 2014 | 706.33 Thousand PLN | 80.55% |
| 2013 | 391.21 Thousand PLN | 13.08% |
| 2012 | 345.94 Thousand PLN | 5.87% |
| 2011 | 326.77 Thousand PLN | 2.34% |
| 2010 | 319.29 Thousand PLN | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 2.11 Million PLN | 0.0% |
| 2024 Q2 | 2.69 Million PLN | 27.24% |
| 2023 Q2 | 2.03 Million PLN | 15.75% |
| 2023 Q1 | 1.75 Million PLN | 0.0% |
| 2023 FY | 2.11 Million PLN | 20.41% |
| 2023 Q4 | 2.11 Million PLN | 4.03% |
| 2023 Q3 | 2.03 Million PLN | 0.0% |
| 2022 Q3 | 1.76 Million PLN | 0.0% |
| 2022 Q1 | 1.95 Million PLN | 0.0% |
| 2022 Q2 | 1.76 Million PLN | -9.88% |
| 2022 FY | 1.75 Million PLN | -10.11% |
| 2022 Q4 | 1.75 Million PLN | -0.25% |
| 2021 Q2 | 3.18 Million PLN | 89.79% |
| 2021 Q1 | 1.67 Million PLN | 0.0% |
| 2021 Q3 | 3.18 Million PLN | 0.0% |
| 2021 Q4 | 1.95 Million PLN | -38.47% |
| 2021 FY | 1.95 Million PLN | 16.78% |
| 2020 Q4 | 1.67 Million PLN | 85.42% |
| 2020 Q1 | 1.58 Million PLN | 0.0% |
| 2020 FY | 1.67 Million PLN | 5.65% |
| 2020 Q2 | 903.72 Thousand PLN | -43.02% |
| 2020 Q3 | 903.72 Thousand PLN | 0.0% |
| 2019 Q2 | 2.1 Million PLN | 5.6% |
| 2019 Q4 | 1.58 Million PLN | 86.72% |
| 2019 Q1 | 1.98 Million PLN | 0.0% |
| 2019 FY | 1.58 Million PLN | -20.27% |
| 2019 Q3 | 849.47 Thousand PLN | -59.57% |
| 2018 Q4 | 1.98 Million PLN | 10.9% |
| 2018 FY | 1.98 Million PLN | 25.04% |
| 2018 Q2 | 1.79 Million PLN | 12.75% |
| 2018 Q1 | 1.59 Million PLN | 0.0% |
| 2018 Q3 | 1.79 Million PLN | 0.0% |
| 2017 Q3 | 1.57 Million PLN | 0.0% |
| 2017 Q4 | 1.59 Million PLN | 1.18% |
| 2017 FY | 1.59 Million PLN | 13.39% |
| 2017 Q2 | 1.57 Million PLN | 12.06% |
| 2017 Q1 | 1.4 Million PLN | 0.0% |
| 2016 Q1 | 1.17 Million PLN | 0.0% |
| 2016 FY | 1.4 Million PLN | 19.52% |
| 2016 Q4 | 1.4 Million PLN | 6.04% |
| 2016 Q3 | 1.32 Million PLN | 0.0% |
| 2016 Q2 | 1.32 Million PLN | 12.72% |
| 2015 Q4 | 1.17 Million PLN | 43.65% |
| 2015 Q1 | 576.77 Thousand PLN | -18.34% |
| 2015 Q2 | 817.34 Thousand PLN | 41.71% |
| 2015 Q3 | 817.34 Thousand PLN | 0.0% |
| 2015 FY | 1.17 Million PLN | 66.22% |
| 2014 Q4 | 706.33 Thousand PLN | 33.69% |
| 2014 FY | 706.33 Thousand PLN | 80.55% |
| 2014 Q1 | 390.42 Thousand PLN | -0.2% |
| 2014 Q2 | 528.32 Thousand PLN | 35.32% |
| 2014 Q3 | 528.32 Thousand PLN | 0.0% |
| 2013 Q3 | 345.75 Thousand PLN | 0.0% |
| 2013 Q4 | 391.21 Thousand PLN | 13.15% |
| 2013 FY | 391.21 Thousand PLN | 13.08% |
| 2013 Q2 | - PLN | 0.0% |
| 2013 Q1 | - PLN | -100.0% |
| 2012 Q4 | 345.94 Thousand PLN | 0.0% |
| 2012 FY | 345.94 Thousand PLN | 5.87% |
| 2011 FY | 326.77 Thousand PLN | 2.34% |
| 2010 FY | 319.29 Thousand PLN | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Bioceltix S.A. | 8617.89 PLN | -24476.782% |
| BIOTON S.A. | 117.91 Million PLN | 98.204% |
| Captor Therapeutics Spolka Akcyjna | - PLN | -Infinity% |
| Mabion S.A. | 6.84 Million PLN | 69.049% |
| Molecure S.A. | - PLN | -Infinity% |
| NanoGroup S.A. | 63.37 Thousand PLN | -3241.854% |
| Pharmena S.A. | 445 Thousand PLN | -375.955% |
| Poltreg S.A. | 415 Thousand PLN | -410.361% |
| Pure Biologics Spólka Akcyjna | 17.56 Million PLN | 87.943% |
| Synthaverse S.A. | 15.48 Million PLN | 86.321% |
| Urteste S.A. | 162 Thousand PLN | -1207.407% |